PMFA
ATRA icon

Plante Moran Financial Advisors’s Atara Biotherapeutics ATRA Stock Holding History

Plante Moran Financial Advisors’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-1
Closed -$1K – 964
2016
Q3 		$1K Sell
1
-1
-50% -$543 ﹤0.01% 883
2016
Q2 		$1K Hold
2
– – ﹤0.01% 847
2016
Q1 		$1K Buy
+2
New +$900 ﹤0.01% 796

Other funds holding ATRA

Baupost Group
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
ArrowMark Colorado Holdings
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock Fund Advisors
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Eagle Asset Management
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
BM
Bridger Management New York $150M AUM 17.71% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Plante Moran Financial Advisors's ATRA Position: Q4 2016 in Review

Plante Moran Financial Advisors sold out of Atara Biotherapeutics (ATRA) in Q4 2016, closing a stake of 1 share — an estimated $1K sold.

Plante Moran Financial Advisors first reported a position in ATRA in Q1 2016 and held it in 3 quarters. The position peaked at $1K in Q3 2016. 86 funds tracked by Wall St. Rank hold ATRA as of Q4 2016.

  • Plante Moran Financial Advisors reported no remaining Atara Biotherapeutics position as of Q4 2016 after selling out during the quarter.
  • Plante Moran Financial Advisors sold 1 Atara Biotherapeutics share in Q4 2016, an estimated $1K.
  • Plante Moran Financial Advisors first reported a position in Atara Biotherapeutics in Q1 2016 and held it in 3 quarters.
  • Plante Moran Financial Advisors's Atara Biotherapeutics position peaked at $1K in Q3 2016.
  • 86 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q4 2016.

Based on Plante Moran Financial Advisors's 13F filing for Q4 2016, filed 27 Jan 2017.